Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Rosewell

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal for Immunotherapy of Cancer|December 9, 2024
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunityDaisuke Morita, Amanda Rosewell Shaw, Greyson Biegert, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2017
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck CancerAmanda Rosewell Shaw, Caroline E Porter, Norihiro Watanabe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 21, 2011
Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transferReeti Khare, Shannon M May, Francesco Vetrini, et al.
Molecular Therapy. Oncology|December 3, 2024
IL-12 encoding oNDV synergizes with CAR-T cells in orthotopic models of non-small cell lung cancerAmanda Rosewell Shaw, Daisuke Morita, Caroline E Porter, et al.
Molecular Therapy. Methods & Clinical Development|July 12, 2024
Mesenchymal stromal cells protect combined oncolytic and helper-dependent adenoviruses from humoral immunityAda Irmak Özcan, Arianexys Aquino Lόpez, Alexandra N Wolff, et al.
Molecular Therapy. Oncology|June 23, 2025
Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinomaGreyson Biegert, Amanda Rosewell Shaw, Daisuke Morita, et al.
Communications Biology|March 20, 2021
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumorsAmanda Rosewell Shaw, Caroline E Porter, Tiffany Yip, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 21, 2010
Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cellsJan-Michael Prill, Sigrid Espenlaub, Ulrike Samen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 8, 2020
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous TumorsCaroline E Porter, Amanda Rosewell Shaw, Youngrock Jung, et al.
Science Advances|March 29, 2023
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studiesDaniel Wang, Caroline E Porter, Bora Lim, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal for Immunotherapy of Cancer|December 9, 2024
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunityDaisuke Morita, Amanda Rosewell Shaw, Greyson Biegert, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2017
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck CancerAmanda Rosewell Shaw, Caroline E Porter, Norihiro Watanabe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 21, 2011
Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transferReeti Khare, Shannon M May, Francesco Vetrini, et al.
Molecular Therapy. Oncology|December 3, 2024
IL-12 encoding oNDV synergizes with CAR-T cells in orthotopic models of non-small cell lung cancerAmanda Rosewell Shaw, Daisuke Morita, Caroline E Porter, et al.
Molecular Therapy. Methods & Clinical Development|July 12, 2024
Mesenchymal stromal cells protect combined oncolytic and helper-dependent adenoviruses from humoral immunityAda Irmak Özcan, Arianexys Aquino Lόpez, Alexandra N Wolff, et al.
Molecular Therapy. Oncology|June 23, 2025
Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinomaGreyson Biegert, Amanda Rosewell Shaw, Daisuke Morita, et al.
Communications Biology|March 20, 2021
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumorsAmanda Rosewell Shaw, Caroline E Porter, Tiffany Yip, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 21, 2010
Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cellsJan-Michael Prill, Sigrid Espenlaub, Ulrike Samen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 8, 2020
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous TumorsCaroline E Porter, Amanda Rosewell Shaw, Youngrock Jung, et al.
Science Advances|March 29, 2023
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studiesDaniel Wang, Caroline E Porter, Bora Lim, et al.
Pageof 2